Behçet disease (BD) was named in 1937 after the Turkish dermatologist Hulusi Behçet, who described the triple-symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis ,  but it is likely that Behçet disease was already described years earlier by Hippocrates, who described a disease with aphthous ulcers and defluxion around genital area, associated with warty ophthalmic conditions. 
Behçet disease is a complex, multisystemic disease that includes involvement of the mucocutaneous, ocular, cardiovascular, renal, gastrointestinal, pulmonary, urologic, and central nervous systems, as well as the joints, blood vessels, and lungs.
The cause of Behçet disease is not known; however, immunogenetics, immune regulation, vascular abnormalities (including arterial and venous abnormalities, affecting small, medium, and large vessels), or bacterial and viral infection may have a role in its development.
Behçet disease is not common in the United States, with a prevalence of 5 cases per 100,000 persons.
A wide geographic variation is noted in the frequency of Behçet disease, with high prevalence in Mediterranean area compared with the United States and Northern Europe. Studies have shown that immigrants from areas with high prevalence rate of Behçet disease remain at high risk of developing Behçet disease.  Behçet disease is most prevalent (and more virulent) in the Mediterranean region, Middle East, and Far East, with an estimated prevalence of 1 case per 10,000 persons.
The prevalence reported in different countries is as follows  :
Turkey: 20-420 cases per 100,000 population
Iran: 16-68 cases per 100,000 population
Israel: 15-120 cases per 100,000 population
Iraq: 17 cases per 100,000 population
Egypt: 7.6 cases per 100,000 population
Spain: 7.5 cases per 100,000 population
Japan: 7-13.5 cases per 100,000 population
Martinique: 7 cases per 100,000 population
France: 7.1 cases per 100,000 population
Italy: 3.8-16 cases per 100,000 population
Northern Europe: 0.5-5 cases per 100,000 population
Men are affected more often, and with more severe disease, than women in some Mediterranean areas. In Iran, for example, the male-to-female ratio was 24:1 among 1712 patients. In Turkey, the ratio was 16:1 among 427 patients.
Onset can occur at any age, but is it most common during the third decade of life.  Behçet disease rarely occurs in individuals older than 50 years or during childhood.  Genetic anticipation was reported in Behçet disease, in which the onset of the disease becomes earlier with successive generations. 
Chronic morbidity is typical; the leading cause is ophthalmic involvement, which can result in blindness. The effects of the disease may be cumulative, especially with neurologic, vascular, and ocular involvement.
The mortality rate is low, but death can occur from neurologic involvement, vascular disease, bowel perforation, cardiopulmonary disease, or as a complication of immunosuppressive therapy. 
A recent study has shown that sub-Saharan African patients with Behçet disease had three times higher mortality compared with North African and European patients, with the 15-year mortality rate reaching 20%, compared with mortality rates of about 5-10% reported in other countries. 
Clinical expression of the disease also shows geographic variation. Sub-Saharan African patients show higher CNS and cardiovascular involvement compared with Behçet disease patients in North Africa and Europe.
Gastrointestinal manifestations and neurological involvement was found to occur at higher rates in American patients compared with Turkish patients. 
Higher rates of folliculitis were found in patients of Iraqi/Iranian origin, and ocular complications were found to be at higher incidence in patients of Arabic origin in a study done on 66 Jewish patients. 
The clinical course of Behçet disease is variable, even in the early stages, making determinations of the long-term prognosis difficult.
Men appear to have a poorer prognosis.
The disease usually runs a protracted course, with attacks generally lasting for several weeks and recurring more frequently early in the disease.
Mucocutaneous and arthritic involvement usually occur early.
Chronic morbidity is usual; the leading cause is ophthalmic involvement, which can result in blindness. The effects of the disease may be cumulative, especially for neurologic, vascular, and ocular involvement.
Mortality is low, but patients may die from neurologic involvement, vascular disease, bowel perforation, cardiopulmonary disease, or as a complication of immunosuppressive therapy.
The risk of cancer was evaluated in a large cohort study including 1,314 patients with Behçet disease. Non-Hodgkin lymphoma, hematologic malignancies, and female breast cancer were the most frequent malignancies observed. The cancer risk was found to be highest within the first year of follow up. 
What would you like to print?